Nordea Investment Management AB Has $3.31 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Nordea Investment Management AB lifted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 22.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 282,834 shares of the company’s stock after buying an additional 52,031 shares during the quarter. Nordea Investment Management AB’s holdings in Roivant Sciences were worth $3,306,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. FMR LLC grew its holdings in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock worth $567,134,000 after acquiring an additional 2,593,910 shares during the period. Rubric Capital Management LP grew its stake in Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock worth $243,110,000 after purchasing an additional 3,000,000 shares during the period. State Street Corp increased its holdings in Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after purchasing an additional 1,118,561 shares in the last quarter. Geode Capital Management LLC lifted its stake in Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares during the period. Finally, DME Capital Management LP grew its position in shares of Roivant Sciences by 14.8% during the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after buying an additional 620,470 shares during the period. Institutional investors own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other news, CIO Mayukh Sukhatme sold 412,584 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $12.05, for a total value of $4,971,637.20. Following the completion of the sale, the executive now owns 18,836,547 shares in the company, valued at $226,980,391.35. This represents a 2.14 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the transaction, the chief operating officer now directly owns 606,525 shares in the company, valued at $6,865,863. The trade was a 14.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,942,629 shares of company stock valued at $23,071,486 over the last ninety days. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $10.63 on Friday. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of 1.88 and a beta of 1.27. Roivant Sciences Ltd. has a fifty-two week low of $9.69 and a fifty-two week high of $13.06. The firm’s 50-day simple moving average is $11.88 and its 200 day simple moving average is $11.58.

Analyst Ratings Changes

ROIV has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.